<DOC>
	<DOCNO>NCT00069238</DOCNO>
	<brief_summary>Background : The paradigm combine therapeutic agent non-overlapping toxicity treatment malignancy produce clinical remission cure number tumor type . A new class agent , humanize chimerized monoclonal antibody , typically little hematopoietic toxicity readily combine full dos cytotoxic chemotherapy . It become clear certain lymphoma breast cancer , combination monoclonal antibody chemotherapy improve response rate quality response compare achieve treatment either agent alone . The clinical outcome patient T-cell non-Hodgkins lymphoma significantly inferior outcome patient B-cell non-Hodgkin lymphoma . In report le 20 % patient T cell lymphoid malignancy remain free disease 5 year . Objectives : Determine toxicity Alemtuzumab etoposide , prednisone , vincristine , cyclophosphamide , doxorubicin ( EPOCH ) chemotherapy untreated cluster differentiation 52 ( CD52 ) -expressing T natural killer ( NK ) lymphoid malignancy . Determine maximum tolerate dose Alemtuzumab administer combination EPOCH chemotherapy . Determine preliminary fashion anti-tumor activity combination Alemtuzumab EPOCH chemotherapy . Eligibility : CD52-expressing lymphoid malignancy . Patients chemotherapy naive aggressive T &amp; NK lymphoma . Patients alk-positive anaplastic large cell lymphoma patient T cell precursor disease eligible . Age great equal 17 year . Adequate organ function , unless impairment due respective organ involvement tumor . No active symptomatic ischemic heart disease , myocardial infarction congestive heart . failure within past year . Human immunodeficiency virus ( HIV ) negative . Not pregnant nursing . Design : Three dose level Alemtuzumab evaluate determine toxicity profile preliminary fashion antitumor activity combination Dose-Adjusted EPOCH . Three dose level Alemtuzumab explore , cohort three six patient . Patients receive either 30 , 60 , 90 mg Alemtuzumab day 1 therapy , follow dose-adjusted EPOCH chemotherapy day 1-5 .</brief_summary>
	<brief_title>Campath-1H EPOCH Treat Non-Hodgkin 's T- NK-Cell Lymphomas</brief_title>
	<detailed_description>Background : The paradigm combine therapeutic agent non-overlapping toxicity treatment malignancy produce clinical remission cure number tumor type . A new class agent , humanize chimerized monoclonal antibody , typically little hematopoietic toxicity readily combine full dos cytotoxic chemotherapy . It become clear certain lymphoma breast cancer , combination monoclonal antibody chemotherapy improve response rate quality response compare achieve treatment either agent alone . The clinical outcome patient T-cell non-Hodgkins lymphoma significantly inferior outcome patient B-cell non-Hodgkins lymphoma . In report le 20 % patient T cell lymphoid malignancy remain free disease 5 year . Objective : Determine toxicity maximum tolerate dose ( MTD ) Alemtuzumab EPOCH chemotherapy untreated cluster differentiation 52 ( CD52 ) -expressing T natural killer ( NK ) lymphoid malignancy Eligibility : - CD52-expressing lymphoid malignancy . - Patients chemotherapy naive aggressive T &amp; NK lymphoma . Patients alk-positive anaplastic large cell lymphoma patient T cell precursor disease eligible . - Age great equal 17 year . - Adequate organ function , unless impairment due respective organ involvement tumor . - No active symptomatic ischemic heart disease , myocardial infarction congestive heart . failure within past year . - Human immunodeficiency virus ( HIV ) negative . - Not pregnant nursing . Design : Three dose level Alemtuzumab evaluate determine toxicity profile preliminary fashion antitumor activity combination Dose-Adjusted etoposide , prednisone , vincristine , cyclophosphamide , doxorubicin ( EPOCH ) . Three dose level Alemtuzumab explore , cohort three six patient . Patients receive either 30 , 60 , 90 mg Alemtuzumab day 1 therapy , follow dose-adjusted EPOCH chemotherapy day 1-5 .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Lymphoma , Extranodal NK-T-Cell</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Alemtuzumab</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>ELIGIBILITY CRITERIA : Cluster differentiation 52 ( CD52 ) express lymphoid malignancy , confirm pathology flow cytometry staff Hematopathology Section , Laboratory Pathology , National Cancer Institute ( NCI ) . Patients T &amp; natural killer ( NK ) cell malignancy without accessible tissue flow cytometry analysis may treat study . Patients chemotherapy naive aggressive T &amp; NK lymphoma , include limited peripheral T cell lymphoma ( otherwise specify ( no ) ) , gammadelta hepatosplenic T cell lymphoma , subcutaneous panniculitislike T cell , NKT cell lymphoma confirm pathology flow cytometry staff Hematopathology Section , Laboratory Pathology , NCI . Patients alkpositive anaplastic large cell lymphoma patient T cell precursor disease eligible . Age great equal 17 year . Laboratory test : Creatinine le equal 1.5 mg/dL creatinine clearance great equal 60 ml/min ; bilirubin less 2.0 mg/dl unless due Gilbert 's , aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) less equal 3 time upper limit normal ( ULN ) ( AST ALT less equal 6 time ULN patient hyperalimentation abnormality felt due hyperalimentation ) ; absolute neutrophil count ( ANC ) great equal 1000/mm ( 3 ) , platelet great equal 75,000/mm ( 3 ) ; unless impairment due respective organ involvement tumor . No active symptomatic ischemic heart disease , myocardial infarction congestive heart failure within past year . Human immunodeficiency virus ( HIV ) negative , unknown effect combine therapy chemotherapy immunosuppressive agent HIV progression . Signed informed consent . Willing use contraception . Not pregnant nursing , unknown effect Alemtuzumab develop fetus infant . No serious underlie medical condition infection would contraindicate treatment . Patients central nervous system ( CNS ) involvement eligible treatment study .</criteria>
	<gender>All</gender>
	<minimum_age>17 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Lymphoma</keyword>
	<keyword>T-Cell Lymphoma</keyword>
	<keyword>NK -Cell Lymphoma</keyword>
</DOC>